Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients
Status:
Unknown status
Trial end date:
2019-04-01
Target enrollment:
Participant gender:
Summary
This study is designed for patients who had malignant melanoma and, following tumor removal,
are now free of disease, or have only very minor residual disease, and are at a very high
risk of disease recurrence. These patients will be treated with the A2/4-1BBL melanoma
vaccine, a compatible melanoma cell line that has been engineered to express a molecule
termed 4-1BBL, which enhances the chances of the cell line to be recognized by the patient's
immune system, and to induce its stimulation. The hypothesis that drives the study states
that the immune response against the cell line will also be effective against the residual
tumor that may still be present in the body.